Sarafan ChEM-H
Showing 101-150 of 236 Results
-
Marie Hollenhorst, MD, PhD
Basic Life Research Scientist, Sarafan ChEM-H
BioDr. Hollenhorst is a physician and scientist with expertise in non-malignant hematology, transfusion medicine, and chemical biology. Dr. Hollenhorst values the one-on-one relationships that she forms with her patients, and strives to deliver the highest quality of care for individuals with blood diseases. Her experience caring for patients drives her to ask scientific questions in the laboratory, where she aims to bring a chemical approach to the study of non-malignant blood disease.
Dr. Hollenhorst pursued combined MD and PhD training at Harvard University, where she received a PhD in Chemical Biology under the mentorship of Professor Christopher T Walsh. She subsequently completed a residency in Internal Medicine at Brigham and Women's Hospital, a fellowship in Transfusion Medicine at Harvard Medical School, and a fellowship in Hematology at Stanford.
Dr. Hollenhorst has an interest in the biology of platelets, which are cellular fragments that help the blood to maintain a healthy balance between bleeding and clotting. Working in the laboratory of Professor Carolyn Bertozzi of Stanford Chemistry, Dr. Hollenhorst is studying sugar molecules found on the surface of platelets that are important in controlling their function and lifespan.
Dr. Hollenhorst's research is supported by an NIH K99 Career Pathway to Independence in Blood Science Award for Physician-Scientists, a Stanford Chemistry, Engineering & Medicine for Human Health Physician-Scientist Fellowship, and a National Blood Foundation Early-Career Scientific Research Grant. -
Michael R. Howitt
Assistant Professor of Pathology and of Microbiology and Immunology
Current Research and Scholarly InterestsOur lab is broadly interested in how intestinal microbes shape our immune system to promote both health and disease. Recently we discovered that a type of intestinal epithelial cell, called tuft cells, act as sentinels stationed along the lining of the gut. Tuft cells respond to microbes, including parasites, to initiate type 2 immunity, remodel the epithelium, and alter gut physiology. Surprisingly, these changes to the intestine rely on the same chemosensory pathway found in oral taste cells. Currently, we aim to 1) elucidate the role of specific tuft cell receptors in microbial detection. 2) To understand how protozoa and bacteria within the microbiota impact host immunity. 3) Discover how tuft cells modulate surrounding cells and tissue.
-
KC Huang
Professor of Bioengineering and of Microbiology and Immunology
Current Research and Scholarly InterestsHow do cells determine their shape and grow?
How do molecules inside cells get to the right place at the right time?
Our group tries to answer these questions using a systems biology approach, in which we integrate interacting networks of protein and lipids with the physical forces determined by the spatial geometry of the cell. We use theoretical and computational techniques to make predictions that we can verify experimentally using synthetic, chemical, or genetic perturbations. -
Ngan F. Huang
Associate Professor of Cardiothoracic Surgery (Cardiothoracic Surgery Research) and, by courtesy, of Chemical Engineering
Current Research and Scholarly InterestsDr. Huang's laboratory aims to understand the chemical and mechanical interactions between extracellular matrix (ECM) proteins and pluripotent stem cells that regulate vascular and myogenic differentiation. The fundamental insights of cell-matrix interactions are applied towards stem cell-based therapies with respect to improving cell survival and regenerative capacity, as well as engineered vascularized tissues for therapeutic transplantation.
-
Possu Huang
Assistant Professor of Bioengineering
Current Research and Scholarly InterestsProtein design: molecular engineering, method development and novel therapeutics
-
Adrian Hugenmatter
Director of Protein Engineering
BioDr. Adrian Hugenmatter joined ChEM-H as Director of Protein Engineering in 2021. In his role, Dr. Hugenmatter heads the Protein Engineering Laboratory at the Nucleus and is responsible for the development of therapeutic proteins at the Innovative Medicines Accelerator (IMA). Dr. Hugenmatter obtained his PhD in the laboratory of Prof. Donald Hilvert at the Swiss Federal Institute of Technology in Zurich (ETH Zurich, Switzerland), where he gained initial experience in the fields of enzymology, antibody engineering and directed evolution. Fascinated by protein engineering, he moved to the laboratory of Prof. Dan Tawfik at the Weizmann Institute of Science (Israel), where he studied molecular evolution and its application in protein design. Dr. Hugenmatter then worked for more than a decade as a researcher and team leader at Roche. During this time, he was involved in the development and optimization of several antibody lead candidates for therapeutic applications in neuroscience and oncology.
-
Paul S Humphries
Alliance Director, Innovative Medicines Accelerator (IMA)
Current Role at StanfordAlliance Director, Stanford Innovative Medicines Accelerator (IMA)
-
Peter K. Jackson
Professor of Microbiology and Immunology (Baxter Labs) and of Pathology
On Partial Leave from 02/01/2025 To 01/31/2026Current Research and Scholarly InterestsCell cycle and cyclin control of DNA replication .
-
Christine Jacobs-Wagner
Dennis Cunningham Professor, Professor of Biology and of Microbiology and Immunology
BioChristine Jacobs-Wagner is a Dennis Cunningham Professor in the Department of Biology and the ChEM-H Institute at Stanford University. She is interested in understanding the fundamental mechanisms and principles by which cells, and, in particular, bacterial cells, are able to multiple. She received her PhD in Biochemistry in 1996 from the University of Liège, Belgium where she unraveled a molecular mechanism by which some bacterial pathogens sense and respond to antibiotics attack to achieve resistance. For this work, she received multiple awards including the 1997 GE & Science Prize for Young Life Scientists. During her postdoctoral work at Stanford Medical School, she demonstrated that bacteria can localize regulatory proteins to specific intracellular regions to control signal transduction and the cell cycle, uncovering a new, unsuspected level of bacterial regulation.
She started her own lab at Yale University in 2001. Over the years, her group made major contributions in the emerging field of bacterial cell biology and provided key molecular insights into the temporal and spatial mechanisms involved in cell morphogenesis, cell polarization, chromosome segregation and cell cycle control. For her distinguished work, she received the Pew Scholars award from the Pew Charitable Trust, the Woman in Cell Biology Junior award from the American Society of Cell Biology and the Eli Lilly award from the American Society of Microbiology. She held the Maxine F. Singer and William H. Fleming professor chairs at Yale. She was elected to the Connecticut academy of Science, the American Academy of Microbiology and the National Academy of Sciences. She has been an investigator of the Howard Hughes Medical Institute since 2008.
Her lab moved to Stanford in 2019. Current research examines the general principles and spatiotemporal mechanisms by which bacterial cells replicate, using Caulobacter crescentus and Escherichia coli as models. Recently, the Jacobs-Wagner lab expanded their interests to the Lyme disease agent Borrelia burgdorferi, revealing unsuspected ways by which this pathogen grows and causes disease -
Amy Jacobson
Director of Microbiome Therapies, Microbiome Therapies Initiative (MITI)
Current Role at StanfordSenior Scientific Program Manager, Sarafan ChEM-H and Stanford Innovative Medicines Accelerator
-
Daniel Jarosz
Associate Professor of Chemical and Systems Biology and of Developmental Biology
Current Research and Scholarly InterestsMy laboratory studies conformational switches in evolution, disease, and development. We focus on how molecular chaperones, proteins that help other biomolecules to fold, affect the phenotypic output of genetic variation. To do so we combine classical biochemistry and genetics with systems-level approaches. Ultimately we seek to understand how homeostatic mechanisms influence the acquisition of biological novelty and identify means of manipulating them for therapeutic and biosynthetic benefit.
-
Michael Christopher Jewett
Professor of Bioengineering
BioMichael Jewett is a Professor of Bioengineering at Stanford University. He received his B.S. from UCLA and PhD from Stanford University, both in Chemical Engineering. He completed postdoctoral studies at the Center for Microbial Biotechnology in Denmark and the Harvard Medical School. Jewett was also a guest professor at the Swiss Federal Institute of Technology (ETH Zurich). His research group focuses on advancing synthetic biology research to support planet and societal health, with applications in medicine, manufacturing, sustainability, and education.
-
Paul A. Khavari, MD, PhD
Carl J. Herzog Professor of Dermatology in the School of Medicine
Current Research and Scholarly InterestsWe work in epithelial tissue as a model system to study stem cell biology, cancer and new molecular therapeutics. Epithelia cover external and internal body surfaces and undergo constant self-renewal while responding to diverse environmental stimuli. Epithelial homeostasis precisely balances stem cell-sustained proliferation and differentiation-associated cell death, a balance which is lost in many human diseases, including cancer, 90% of which arise in epithelial tissues.
-
Chaitan Khosla
Wells H. Rauser and Harold M. Petiprin Professor and Professor of Chemistry and, by courtesy, of Biochemistry
Current Research and Scholarly InterestsResearch in this laboratory focuses on problems where deep insights into enzymology and metabolism can be harnessed to improve human health.
For the past two decades, we have studied and engineered enzymatic assembly lines called polyketide synthases that catalyze the biosynthesis of structurally complex and medicinally fascinating antibiotics in bacteria. An example of such an assembly line is found in the erythromycin biosynthetic pathway. Our current focus is on understanding the structure and mechanism of this polyketide synthase. At the same time, we are developing methods to decode the vast and growing number of orphan polyketide assembly lines in the sequence databases.
For more than a decade, we have also investigated the pathogenesis of celiac disease, an autoimmune disorder of the small intestine, with the goal of discovering therapies and related management tools for this widespread but overlooked disease. Ongoing efforts focus on understanding the pivotal role of transglutaminase 2 in triggering the inflammatory response to dietary gluten in the celiac intestine. -
Peter S. Kim
Virginia and D. K. Ludwig Professor of Biochemistry
Current Research and Scholarly InterestsOur research focuses on developing new strategies for vaccine creation. We also aim to generate vaccines targeting infectious agents that have eluded efforts to date. We integrate experimental approaches with protein language models to guide artificial evolution and enable efficient antibody and protein engineering. Our interdisciplinary approach aims to address critical global health challenges.
-
Karla Kirkegaard
Violetta L. Horton Professor and Professor of Microbiology and Immunology
Current Research and Scholarly InterestsThe biochemistry of RNA-dependent RNA polymerase function, the cell biology of the membrane rearrangements induced by positive-strand RNA virus infection of human cells, and the genetics of RNA viruses, which, with their high error rates, live at the brink of error catastrophe, are investigated in the Kirkegaard laboratory.
-
Bruce Koch, Ph.D.
Director of High-Throughput Screening
Current Role at StanfordDirector, ChEM-H/CSB High Throughput Screening Group
Staff Lead, IMA HTS Module
Adviser to the SPARK Program -
Eric Kool
George A. and Hilda M. Daubert Professor of Chemistry
Current Research and Scholarly Interests• Design of cell-permeable reagents for profiling, modifying, and controlling RNAs
• Developing fluorescent probes of DNA repair pathways, with applications in cancer, aging, and neurodegenerative disease
• Discovery and development of small-molecule modulators of DNA repair enzymes, with focus on cancer and inflammation -
Tobias Lanz
Assistant Professor of Medicine (Immunology and Rheumatology)
BioTobias Lanz, MD is an Assistant Professor at the Institute for Immunity, Transplantation, and Infection and the Division of Immunology and Rheumatology at Stanford. His research focuses on B cell biology in neuroimmunological diseases and rheumatic diseases with neurological manifestations. He uses high-throughput screening technologies, and methods from structural and cell biology to identify new autoantigens and to understand how certain self-reactive B cells escape tolerance mechanisms. He is particularly interested in molecular mechanisms that explain the association between Epstein Barr Virus (EBV) and autoimmunity.
Tobias went to medical school at the Eberhard Karls University in Tübingen, Germany and at the University College of London. He wrote his MD thesis at Dr. Michael Platten's laboratory at the Hertie Institute for Clinical Brain Research in Tübingen, Germany before joining Dr. Lawrence Steinman’s neuroimmunological laboratory at Stanford as a research scholar. After medical school he pursued his scientific and clinical training at the German Cancer Research Center (DKFZ) and the Department of Neurology at the University Hospital in Heidelberg, Germany. In 2015 he joined Dr. William Robinson’s lab at Stanford, where he investigated environmental triggers of autoimmunity, including viruses and milk consumption. In his most recent work, he characterized the B cell repertoire in the spinal fluid of patients with multiple sclerosis (MS) and identified molecular mimicry between EBV EBNA1 and the glial cellular adhesion molecule GlialCAM as a driver of neuroinflammation (Lanz et al., Nature, 2022). His long term objective is to leverage these newly discovered mechanistic insights to develop next-generation biomarkers and therapeutics for autoimmune diseases. -
Jin Billy Li
Professor of Genetics
Current Research and Scholarly InterestsThe Li Lab is primarily interested in RNA editing mediated by ADAR enzymes. We co-discovered that the major function of RNA editing is to label endogenous dsRNAs as "self" to avoid being recognized as "non-self" by MDA5, a host innate immune dsRNA sensor, leading us to pursue therapeutic applications in cancer, autoimmune diseases, and viral infection. The other major direction of the lab is to develop technologies to harness endogenous ADAR enzymes for site-specific transcriptome engineering.
-
Lingyin Li
Professor of Biochemistry
BioDr. Li is a professor in the Biochemistry Department and ChEM-H Institute at Stanford. She is also a core investigator of the Arc Institute. Her lab works on understanding biochemical mechanisms of the immunotransmitter cGAMP and harnessing it to treat cancer and autoimmunity. She majored in chemistry at University of Science and Technology of China and graduated with a B. En in 2003. She then trained with Dr. Laura Kiessling, a pioneer in chemical biology, at University of Wisconsin-Madison and graduated with a Ph.D in chemistry in 2010. She obtained her postdoctoral training with Dr. Timothy Mitchison at Harvard Medical School, who introduced her to the field of chemical immunology. She started her lab at Stanford in 2015.
-
Michael Lin
Professor of Neurobiology and of Bioengineering
Current Research and Scholarly InterestsOur lab applies biochemical and engineering principles to the development of protein-based tools for investigating biology in living animals. Topics of investigation include fluorescent protein-based voltage indicators, synthetic light-controllable proteins, bioluminescent reporters, and applications to studying animal models of disease.
-
Kyle Loh
Assistant Professor of Developmental Biology (Stem Cell)
BioHow the richly varied cell-types in the human body arise from one embryonic cell is a biological marvel and mystery. We have mapped how human embryonic stem cells develop into over twenty different human cell-types. This roadmap allowed us to generate enriched populations of human liver, bone, heart and blood vessel cells in a Petri dish from embryonic stem cells. Each of these human cells could regenerate their cognate tissue upon injection into respective mouse models, with relevance to regenerative medicine. In addition to developmental and stem cell biology, we have an emerging interest in exploring deadly biosafety level 4 viruses together with our collaborators.
Kyle attended the County College of Morris and Rutgers, and received his Ph.D. from Stanford (working with Irving Weissman), with fellowships from the Hertz Foundation, National Science Foundation and Davidson Institute for Talent Development. He then continued as a Siebel Investigator, and later, as an Assistant Professor and The Anthony DiGenova Endowed Faculty Scholar at Stanford, where he is jointly appointed in the Department of Developmental Biology and Institute for Stem Cell Biology & Regenerative Medicine. Kyle is a Packard Fellow, Pew Scholar, Human Frontier Science Program Young Investigator and Baxter Foundation Faculty Scholar, and his research has been recognized by the NIH Director's Early Independence Award, Forbes 30 Under 30, Harold Weintraub Graduate Award, Hertz Foundation Thesis Prize and A*STAR Investigatorship. -
Jonathan Z. Long
Associate Professor of Pathology
BioDr. Jonathan Long is an Associate Professor of Pathology and an Institute Scholar of Stanford ChEM-H (Chemistry, Engineering & Medicine for Human Health). His laboratory studies signaling pathways in mammalian energy metabolism. The long-term goal of this program is to discover new molecules and pathways that can be translated into therapeutic opportunities for obesity, metabolic disease, and other age-associated chronic diseases. Work from the laboratory has been recognized by numerous awards from the Alfred P. Sloan Foundation, the National Institutes of Health, the American Diabetes Association, and the Ono Pharma Foundation. Prior to arriving to Stanford, Dr. Long completed his Ph.D. in Chemistry at Scripps Research and his postdoctoral work at Harvard Medical School.
-
Sharon R. Long
William C. Steere, Jr. - Pfizer Inc. Professor of Biological Sciences and Professor, by courtesy, of Biochemistry
Current Research and Scholarly InterestsBiochemistry, genetics and cell biology of plant-bacterial symbiosis
-
Anson Lowe
Associate Professor of Medicine (Gastroenterology and Hepatology), Emeritus
Current Research and Scholarly InterestsThe laboratory is focused on the relationship between injury, wound healing, and cancer. Esophageal, gastric, and pancreatic cancers are a focus. We are particularly interested in the regulation of cell signaling by EGFR, the EGF receptor. In addition to cancer pathogenesis, active projects include the development of new diagnostic assays and drugs.
-
Sydney X. Lu
Assistant Professor of Medicine (Hematology)
BioSydney Lu is an assistant professor and physician-scientist in the Division of Hematology, Department of Medicine with a broad interest in both normal and abnormal RNA processing in the context of normal physiology and disease states. The laboratory studies translational questions regarding the mechanistic basis of RNA processing abnormalities in malignant blood disorders, their implications for leukemogenesis and cancer biology, as well as resultant therapeutic opportunities.
As a physician, Sydney’s group is particularly focused on dissecting RNA processing abnormalities in primary patient samples and disease-relevant preclinical model systems. Lab members employ a variety of ‘wet-lab’ and computational approaches to study transcriptome abnormalities in (1) states of immune dysfunction, (2) myeloid blood cancers such as myelodysplastic syndromes and acute myeloid leukemia, and (3) lymphoid blood cancers such as chronic lymphocytic leukemia. Additional projects are focused on novel therapeutics, including multiple targeted agents which modulate RNA processing, for the selective treatment of these diseases.
Sydney’s research is/has been supposed by grant funding from the National Cancer Institute, Parker Institute for Cancer Immunotherapy, Leukemia & Lymphoma Society, Aplastic Anemia & Myelodysplastic Syndromes International Foundation, the American Society for Clinical Oncology, the American Society of Hematology, the American Association for Cancer Research, the Paula and Rodger Riney Foundation, the Doris Duke Charitable Foundation, The Gabrielles Angel Foundation for Cancer Research, and the Stanford Cancer Institute. -
Liqun Luo
Ann and Bill Swindells Professor and Professor, by courtesy, of Neurobiology
Current Research and Scholarly InterestsWe study how neurons are organized into specialized circuits to perform specific functions and how these circuits are assembled during development. We have developed molecular-genetic and viral tools, and are combining them with transcriptomic, proteomic, physiological, and behavioral approaches to study these problems. Topics include: 1) assembly of the fly olfactory circuit; 2) assembly of neural circuits in the mouse brain; 3) organization and function of neural circuits; 4) Tool development.
-
Ruben Y. Luo
Assistant Professor of Pathology
Current Research and Scholarly InterestsApply top-down mass spectrometry and label-free immunoassay to the study and utilization of biomarker proteoforms in clinical diagnosis.
-
Vinit B. Mahajan, MD, PhD
Professor of Ophthalmology
Current Research and Scholarly InterestsOur focus is the development of personalized medicine for eye diseases through translation of our discoveries in proteomics, genomics, and phenomics in humans, mice and tissue culture models.
-
Nicole M. Martinez
Assistant Professor of Chemical and Systems Biology and of Developmental Biology
Current Research and Scholarly InterestsThe Martinez lab studies RNA regulatory mechanisms that control gene expression. We focus on mRNA processing, RNA modifications and their roles in development and disease.
-
Michaëlle Ntala Mayalu
Assistant Professor of Mechanical Engineering and, by courtesy, of Bioengineering
BioDr. Michaëlle N. Mayalu is an Assistant Professor of Mechanical Engineering. She received her Ph.D., M.S., and B.S., degrees in Mechanical Engineering at the Massachusetts Institute of Technology. She was a postdoctoral scholar at the California Institute of Technology in the Computing and Mathematical Sciences Department. She was a 2017 California Alliance Postdoctoral Fellowship Program recipient and a 2019 Burroughs Wellcome Fund Postdoctoral Enrichment Program award recipient. She is also a 2023 Hypothesis Fund Grantee.
Dr. Michaëlle N. Mayalu's area of expertise is in mathematical modeling and control theory of synthetic biological and biomedical systems. She is interested in the development of control theoretic tools for understanding, controlling, and predicting biological function at the molecular, cellular, and organismal levels to optimize therapeutic intervention.
She is the director of the Mayalu Lab whose research objective is to investigate how to optimize biomedical therapeutic designs using theoretical and computational approaches coupled with experiments. Initial project concepts include: i) theoretical and experimental design of bacterial "microrobots" for preemptive and targeted therapeutic intervention, ii) system-level multi-scale modeling of gut associated skin disorders for virtual evaluation and optimization of therapy, iii) theoretical and experimental design of "microrobotic" swarms of engineered bacteria with sophisticated centralized and decentralized control schemes to explore possible mechanisms of pattern formation. The experimental projects in the Mayalu Lab utilize established techniques borrowed from the field of synthetic biology to develop synthetic genetic circuits in E. coli to make bacterial "microrobots". Ultimately the Mayalu Lab aims to develop accurate and efficient modeling frameworks that incorporate computation, dynamical systems, and control theory that will become more widespread and impactful in the design of electro-mechanical and biological therapeutic machines. -
Nicholas Melosh
Professor of Materials Science and Engineering
On Leave from 04/01/2025 To 06/30/2025BioThe Melosh group explores how to apply new methods from the semiconductor and self-assembly fields to important problems in biology, materials, and energy. We think about how to rationally design engineered interfaces to enhance communication with biological cells and tissues, or to improve energy conversion and materials synthesis. In particular, we are interested in seamlessly integrating inorganic structures together with biology for improved cell transfection and therapies, and designing new materials, often using diamondoid molecules as building blocks.
My group is very interested in how to design new inorganic structures that will seamless integrate with biological systems to address problems that are not feasible by other means. This involves both fundamental work such as to deeply understand how lipid membranes interact with inorganic surfaces, electrokinetic phenomena in biologically relevant solutions, and applying this knowledge into new device designs. Examples of this include “nanostraw” drug delivery platforms for direct delivery or extraction of material through the cell wall using a biomimetic gap-junction made using nanoscale semiconductor processing techniques. We also engineer materials and structures for neural interfaces and electronics pertinent to highly parallel data acquisition and recording. For instance, we have created inorganic electrodes that mimic the hydrophobic banding of natural transmembrane proteins, allowing them to ‘fuse’ into the cell wall, providing a tight electrical junction for solid-state patch clamping. In addition to significant efforts at engineering surfaces at the molecular level, we also work on ‘bridge’ projects that span between engineering and biological/clinical needs. My long history with nano- and microfabrication techniques and their interactions with biological constructs provide the skills necessary to fabricate and analyze new bio-electronic systems.
Research Interests:
Bio-inorganic Interface
Molecular materials at interfaces
Self-Assembly and Nucleation and Growth -
Timothy Meyer
Stanford University Professor of Nephrology, Emeritus
Current Research and Scholarly InterestsInadequate removal of uremic solutes contributes to widespread illness in the more than 500,000 Americans maintained on dialysis. But we know remarkably little about these solutes. Dr. Meyer's research efforts are focused on identifying which uremic solutes are toxic, how these solutes are made, and how their production could be decreased or their removal could be increased. We should be able to improve treatment if we knew more about what we are trying to remove.
-
Paul Salomon Mischel
Fortinet Founders Professor and Professor, by courtesy, of Neurosurgery
Current Research and Scholarly InterestsMy research bridges cancer genetics, signal transduction and cellular metabolism as we aim to understand the molecular mechanisms that drive cancer development, progression, and drug resistance. We have made a series of discoveries that have identified a central role for ecDNA (extrachromosomal DNA) in cancer development, progression, accelerated tumor evolution and drug resistance.